Adcetris for systemic Anaplastic Large Cell Lymphoma - Details


( Dernière mise à jour : décembre 20, 2013)
Generic Name:
Brentuximab vedotin
État du projet:
Terminé
Domaine thérapeutique:
Systemic Anaplastic Large Cell Lymphoma
Fabricant:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Gamme de produits:
Examen en vue du remboursement

Détails


Strength:
50mg/vial
Tumour Type:
Lymphoma
Indications:
Systemic Anaplastic Large Cell Lymphoma
Funding Request:
For second-line treatment of sALCL patients - i.e. after failure of at least one prior multi-agent chemotherapy regimen
Review Status:
Complete
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
Time required for the submitter to provide additional economic information has impacted the review timeline.
Recommandation:
Remboursement sous critères cliniques ou conditions
Clarification:
Time required for the submitter to provide additional economic information has impacted the review timeline.
Funding Request:
For second-line treatment of sALCL patients - i.e. after failure of at least one prior multi-agent chemotherapy regimen
pERC Meeting:
Final Recommendation Issued:

Fichiers

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.